Technical Hurdles, Commercial Limits Complicate Supplement-To-Drug Moves
Firms should investigate regulatory hurdles and gauge the commercial appeal of a finished product before moving dietary supplement ingredients into the pharmaceutical realm, say manufacturing and testing consultants
You may also be interested in...
Ovos Natural Health plans a 2010 U.S. launch of its Vivimind cognitive health supplement, contingent upon FDA's go-ahead
FDA should move dietary supplement firms out of "limbo" when it comes to the rules for using scientific studies in developing new products, industry supporters in the House say
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011